Brevan Howard Capital Management LP Grows Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Brevan Howard Capital Management LP raised its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 140.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 52,841 shares of the medical device company's stock after buying an additional 30,909 shares during the quarter. Brevan Howard Capital Management LP owned about 0.08% of Tandem Diabetes Care worth $1,903,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. AlphaQuest LLC grew its position in Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after purchasing an additional 541 shares during the period. Jones Financial Companies Lllp raised its holdings in shares of Tandem Diabetes Care by 195.8% in the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after purchasing an additional 748 shares during the last quarter. Assetmark Inc. lifted its position in shares of Tandem Diabetes Care by 77.5% during the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after purchasing an additional 535 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in Tandem Diabetes Care by 163.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock worth $65,000 after purchasing an additional 1,101 shares during the last quarter. Finally, Venturi Wealth Management LLC grew its position in Tandem Diabetes Care by 5,955.9% in the 4th quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company's stock worth $74,000 after purchasing an additional 2,025 shares in the last quarter.

Wall Street Analysts Forecast Growth

TNDM has been the topic of a number of research analyst reports. Stifel Nicolaus dropped their target price on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Robert W. Baird reduced their price objective on Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating for the company in a report on Thursday, May 1st. Morgan Stanley cut Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and dropped their price target for the company from $45.00 to $22.00 in a research report on Wednesday, March 5th. Barclays lowered their price objective on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Finally, Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Tandem Diabetes Care currently has an average rating of "Moderate Buy" and an average target price of $39.81.

Insiders Place Their Bets

In related news, COO Jean-Claude Kyrillos bought 10,538 shares of the stock in a transaction on Friday, March 7th. The shares were bought at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the transaction, the chief operating officer now owns 10,538 shares of the company's stock, valued at $190,948.56. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.90% of the stock is owned by corporate insiders.

Tandem Diabetes Care Trading Up 1.2%

Shares of Tandem Diabetes Care stock traded up $0.29 during mid-day trading on Monday, hitting $23.27. The stock had a trading volume of 653,655 shares, compared to its average volume of 1,494,983. Tandem Diabetes Care, Inc. has a 12-month low of $15.75 and a 12-month high of $53.69. The firm has a market cap of $1.55 billion, a P/E ratio of -12.12 and a beta of 1.47. The firm has a 50-day moving average of $18.66 and a two-hundred day moving average of $28.14. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The firm had revenue of $234.42 million during the quarter, compared to analyst estimates of $220.19 million. During the same period in the prior year, the firm earned ($0.65) earnings per share. The business's revenue was up 22.3% compared to the same quarter last year. Sell-side analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.